Description
The abstract states that apoE4 drives earlier and more abundant amyloids, but the precise molecular mechanisms explaining this isoform-specific difference in amyloid seeding are not detailed. Understanding these mechanisms is critical for developing targeted therapeutic interventions.
Gap type: unexplained_observation Source paper: ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. (2022, Mol Neurodegener, PMID:36348357)
Resolution criteria
Resolution requires: (1) Biochemical assays (co-immunoprecipitation, pull-down) identifying specific apoE4-amyloid beta interaction domains with >=2-fold difference in binding affinity (KD) from apoE2/E3; (2) Cell-based validation in iPSC-derived neurons or astrocytes showing apoE4 increases A-beta production/aggregation rate by >=30% compared to apoE2/E3; (3) Animal model evidence (APP/PS1 x APOE knock-in mice) demonstrating mechanistic link between identified domain and accelerated plaque formation in vivo. Observational correlations without mechanistic validation are insufficient.